{"entity":{"id":"japan-conditional-early-approval","kind":"term","name":"Japan conditional early approval and time-limited approval","aka":["conditional early approval system","conditional and time-limited approval","PMD Act 2019 amendment","Pharmaceuticals and Medical Devices Act","regenerative medicine conditional approval","Japan conditional approval"],"tldr":"Japan can approve a medicine for a serious disease on early data when a confirmatory trial would be hard to run, on condition that evidence is gathered after launch; for cell and tissue products a 2014 law allows a time-limited approval that must be confirmed within seven years.","summary":"Japan, statute. The 2014 amendments to the Pharmaceuticals and Medical Devices Act (PMD Act) created a conditional and time-limited approval for regenerative medical products, valid for up to seven years, on the basis of probable benefit and confirmed safety. A separate conditional early approval system for drugs was piloted by the Ministry of Health, Labour and Welfare from 2017 and given statutory footing by the 2019 amendment to the PMD Act, effective in 2020, alongside the Sakigake designation. Primary text: the PMDA's English pages on the Act and its review programmes.\n\nHow it works: a drug for a serious disease where a confirmatory trial is difficult or would take too long, and where exploratory trials show a certain level of efficacy and safety, may be approved with conditions such as post-marketing studies, registries and use restricted to specified institutions; the approval is reconsidered when the required data arrive. For regenerative products the time-limited approval must be converted to full approval, or lapse, within the set period.\n\nWhy it matters for oncology and the arguments: the systems are Japan's counterparts to the FDA's accelerated approval and the EU's conditional authorisation, and several cancer cell therapies and rare-cancer drugs have used them. The regenerative product route drew international criticism when products were approved on small, uncontrolled studies, and a few later failed to confirm benefit; supporters answer that the time limit is a stronger discipline than the open-ended confirmatory obligations that plagued accelerated approvals in the United States before the 2022 reforms.","asOf":"2026-09-17","links":[{"label":"PMDA (English)","url":"https://www.pmda.go.jp/english/"}],"tags":["law","jp"],"related":["sakigake","accelerated-approval","conditional-approval","fdora-2022","confirmatory-trial","regulatory-agencies","fast-track-rmat"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["pmda"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/japan-conditional-early-approval/","neighbours":{"term":[{"id":"accelerated-approval","kind":"term","name":"Accelerated approval","route":"/terms/accelerated-approval/"},{"id":"conditional-approval","kind":"term","name":"Conditional marketing authorisation (EU)","route":"/terms/conditional-approval/"},{"id":"confirmatory-trial","kind":"term","name":"Confirmatory trial","route":"/terms/confirmatory-trial/"},{"id":"fast-track-rmat","kind":"term","name":"Fast Track and RMAT designations","route":"/terms/fast-track-rmat/"},{"id":"fdora-2022","kind":"term","name":"FDORA 2022 accelerated approval reforms","route":"/terms/fdora-2022/"},{"id":"full-approval","kind":"term","name":"Full (traditional, regular) approval","route":"/terms/full-approval/"},{"id":"regulatory-agencies","kind":"term","name":"Regulators beyond the FDA (EMA/CHMP, MHRA, PMDA, NMPA, TGA)","route":"/terms/regulatory-agencies/"},{"id":"sakigake","kind":"term","name":"Sakigake designation (Japan)","route":"/terms/sakigake/"}],"institution":[{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/"}],"bottleneck":[{"id":"b-regulatory-fragmentation","kind":"bottleneck","name":"Regulatory divergence between regions","route":"/bottlenecks/b-regulatory-fragmentation/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}]}}